sofosbuvir has been researched along with grazoprevir in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 8 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Dadej, A; Jelińska, A; Muszalska, I; Sobczak, A; Tomczak, S; Zając, M | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E | 1 |
| Hubbard, H; Lawitz, E; Vizuete, J | 1 |
| Asselah, T; Boyer, N; Marcellin, P; Martinot-Peignoux, M; Saadoun, D | 1 |
| Nelson, DR; Peter, J | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Pinchera, B; Scotto, R; Zappulo, E | 1 |
| Park, SH | 1 |
| Hussar, DA | 1 |
| Cheng, PN; Chiu, YC; Sun, HY; Tsai, WJ; Tseng, CY; Young, KC | 1 |
| Alric, L; Bellissant, E; Bourlière, M; de Lédinghen, V; Gibowski, S; Hézode, C; Jézéquel, C; Laforest, C; Larrey, D; Métivier, S; Pailhé, A; Pawlotsky, JM; Pol, S; Renault, A; Samuel, D; Tran, A; Tual, C; Zoulim, F | 1 |
| Bair, N; Bowring, MG; Brown, DM; Chattergoon, MA; Desai, NM; Durand, CM; Massaccesi, G; Naqvi, FF; Ostrander, D; Reyad, A; Segev, DL; Sugarman, J; Sulkowski, M; Wesson, R | 1 |
| Amador, J; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Rajender Reddy, K; Reau, N; Reeve, BB; Sarkar, S; Serper, M; Sterling, RK; Stewart, PW | 1 |
| Arachchi, N; Bowden, S; Cameron, K; Doyle, J; Gow, P; Hellard, M; Iser, D; O'Keefe, J; Papaluca, T; Pianko, S; Sievert, W; Sinclair, M; Stoove, M; Thompson, A | 1 |
| Antón, JJ; Arenas, JI; Bernal, E; Casado, M; Chueca, N; Collado, A; De la Iglesia, A; Espinosa, MD; García, F; García-Bujalance, S; García-Deltoro, M; García-Herola, A; Hernández-Quero, J; Hidalgo-Tenorio, C; Lozano, AB; Macías, J; Martínez, O; Omar, M; Pascasio, JM; Pérez, AB; Pineda, JA; Rincón, P; Ríos, MJ; Rivero-Juárez, A; Rosales, JM; Salmerón, J; Santos, J; Selfa, A; Téllez, F; Vélez, M; Von-Wichmann, MÁ | 1 |
| Barash, D; Chayama, K; Churkin, A; Cotler, SJ; Dahari, H; Dasgupta, S; Etzion, O; Gorstein, E; Imamura, M; Nakahara, T; Tsuge, M; Uprichard, SL; Yardeni, D | 1 |
| Chen, YC; Cheng, YT; Chien, RN; Hsieh, YC; Jeng, WJ; Lin, CY; Liu, YC; Sheen, IS; Teng, W | 1 |
| Chen, H; Li, C; Liang, J; Tian, J; Xiang, H | 1 |
| Hidaka, I; Hirao, T; Ishida, H; Sakaida, I; Suenaga, R; Suka, M | 1 |
| Guo, M; Ke, L; Liu, J; You, R | 1 |
| Dong, M; Evon, DM; Lok, AS; Michael, L; Nelson, DR; Peter, J; Reeve, BB; Stewart, PW | 1 |
| Biering, SB; Chien, M; Dugast-Darzacq, C; Garzia, A; Graham, TGW; Jockusch, S; Ju, J; Meyer, C; Näär, AM; Nguyenla, X; Patel, DJ; Russo, JJ; Schaletzky, J; Stanley, S; Stroumza, J; Tao, C; Tuschl, T; Van Dis, E; Wang, X; Wehri, E; Xie, W; Yamashiro, LH; Zhu, C | 1 |
9 review(s) available for sofosbuvir and grazoprevir
| Article | Year |
|---|---|
Hepatitis C - New drugs and treatment prospects.
Topics: Animals; Antiviral Agents; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Hepatitis C; Humans; Molecular Structure; Molecular Targeted Therapy; Protease Inhibitors | 2019 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.
Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Discovery; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Indoles; Isoquinolines; MicroRNAs; Molecular Targeted Therapy; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Nonstructural Proteins | 2015 |
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2016 |
Hepatitis C virus: how to provide the best treatment with what I have.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Young Adult | 2016 |
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.
Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Cyclopropanes; Drugs, Investigational; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Quinoxalines; Sofosbuvir; Sulfonamides | 2016 |
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].
Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Practice Guidelines as Topic; Quinoxalines; Republic of Korea; Sofosbuvir; Sulfonamides | 2016 |
NewDrugs 2017, part 2.
Topics: Amides; Antibodies, Monoclonal, Humanized; Benzofurans; Carbamates; Cyclopropanes; Drug Approval; Drug Therapy; gamma-Cyclodextrins; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Peptides; Phenylalanine; Quinoxalines; Sofosbuvir; Sugammadex; Sulfonamides; Sulfones; Thioglycolates; Triazoles; United States; United States Food and Drug Administration | 2017 |
Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides | 2022 |
4 trial(s) available for sofosbuvir and grazoprevir
| Article | Year |
|---|---|
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Graft Rejection; Graft Survival; Hepatitis C; Humans; Imidazoles; Kidney; Kidney Transplantation; Male; Middle Aged; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Tissue Donors; Treatment Outcome | 2018 |
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
Topics: Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Sofosbuvir; Sulfonamides | 2022 |
9 other study(ies) available for sofosbuvir and grazoprevir
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Lipids; Male; Middle Aged; Quinoxalines; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2018 |
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Proline; Prospective Studies; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2019 |
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Quinoxalines; Ribavirin; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins | 2019 |
Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.
Topics: Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Duration of Therapy; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Models, Theoretical; Pyrrolidines; Quinoxalines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Time Factors | 2020 |
Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients.
Topics: Adult; Alanine Transaminase; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Liver; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quinoxalines; Retrospective Studies; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2020 |
Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.
Topics: Alanine Transaminase; Amides; Antiviral Agents; Aspartate Aminotransferases; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Quinoxalines; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load | 2020 |
Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Young Adult | 2021 |
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Hepacivirus; Hepatitis C; Humans; Lung; Nucleosides; SARS-CoV-2; Sofosbuvir | 2022 |